Morgan Stanley’s AYTU BioPharma AYTU Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $269 | Hold |
125
| – | – | ﹤0.01% | 7801 |
|
|
2026
Q1 | $341 | Hold |
125
| – | – | ﹤0.01% | 7657 |
|
|
2025
Q4 | $325 | Sell |
125
-161
| -56% | -$361 | ﹤0.01% | 7576 |
|
|
2025
Q3 | $538 | Hold |
286
| – | – | ﹤0.01% | 7485 |
|
|
2025
Q2 | $624 | Sell |
286
-4
| -1% | -$6 | ﹤0.01% | 7403 |
|
|
2025
Q1 | $348 | Hold |
290
| – | – | ﹤0.01% | 7413 |
|
|
2024
Q4 | $493 | Hold |
290
| – | – | ﹤0.01% | 7344 |
|
|
2024
Q3 | $681 | Sell |
290
-150
| -34% | -$389 | ﹤0.01% | 7271 |
|
|
2024
Q2 | $1.28K | Sell |
440
-620
| -58% | -$1.87K | ﹤0.01% | 7128 |
|
|
2024
Q1 | $3.22K | Sell |
1,060
-340
| -24% | -$973 | ﹤0.01% | 6989 |
|
|
2023
Q4 | $3.98K | Hold |
1,400
| – | – | ﹤0.01% | 6888 |
|
|
2023
Q3 | $3.78K | Buy |
1,400
+960
| +218% | +$1.68K | ﹤0.01% | 6979 |
|
|
2023
Q2 | $704 | Sell |
440
-584
| -57% | -$1.15K | ﹤0.01% | 7343 |
|
|
2023
Q1 | $2.29K | Sell |
1,024
-1
| -0.1% | -$3 | ﹤0.01% | 7215 |
|
|
2022
Q4 | $3.87K | Buy |
1,025
+1
| +0.1% | +$4 | ﹤0.01% | 7217 |
|
|
2022
Q3 | $4K | Sell |
1,024
-250
| -20% | -$1.9K | ﹤0.01% | 7289 |
|
|
2022
Q2 | $17K | Sell |
1,274
-1,287
| -50% | -$16.5K | ﹤0.01% | 7040 |
|
|
2022
Q1 | $56K | Sell |
2,561
-6,946
| -73% | -$173K | ﹤0.01% | 6646 |
|
|
2021
Q4 | $257K | Sell |
9,507
-9,389
| -50% | -$406K | ﹤0.01% | 5928 |
|
|
2021
Q3 | $1.09M | Buy |
18,896
+16,781
| +793% | +$1.26M | ﹤0.01% | 4997 |
|
|
2021
Q2 | $212K | Buy |
2,115
+2,046
| +2,965% | +$240K | ﹤0.01% | 5983 |
|
|
2021
Q1 | $10K | Sell |
69
-667
| -91% | -$106K | ﹤0.01% | 6928 |
|
|
2020
Q4 | $87K | Buy |
736
+693
| +1,612% | +$126K | ﹤0.01% | 5966 |
|
|
2020
Q3 | $10K | Sell |
43
-17
| -28% | -$4.37K | ﹤0.01% | 6267 |
|
|
2020
Q2 | $17K | Buy |
60
+51
| +567% | +$15.4K | ﹤0.01% | 6042 |
|
|
2020
Q1 | $3K | Sell |
9
-190
| -95% | -$36.7K | ﹤0.01% | 6312 |
|
|
2019
Q4 | $39K | Buy |
+199
| New | +$38.2K | ﹤0.01% | 5926 |
|
|
2019
Q3 | – | Hold |
0
| – | – | – | 6633 |
|
|
2019
Q2 | – | Hold |
0
| – | – | – | 6642 |
|
|
2019
Q1 | – | Hold |
0
| – | – | – | 6590 |
|
|
2018
Q4 | – | Hold |
0
| – | – | – | 6593 |
|
|
2018
Q3 | – | Hold |
0
| – | – | – | 6709 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 6662 |
|
|
2018
Q1 | – | Hold |
0
| – | – | – | 6607 |
|
|
2017
Q4 | – | Hold |
0
| – | – | – | 6565 |
|
Other funds holding AYTU
NCM
SCM
AIC
CAM
DP
Morgan Stanley's AYTU Position: Q2 2026 in Review
Morgan Stanley held its AYTU BioPharma (AYTU) position steady in Q2 2026 at 125 shares worth $269. The position accounts for ﹤0.01% of the portfolio, ranked #7801.
Morgan Stanley first reported a position in AYTU in Q4 2019 and has held it in 27 quarters since. The position peaked at $1.09M in Q3 2021. 38 funds tracked by Wall St. Rank hold AYTU as of Q2 2026.
- Morgan Stanley held 125 shares of AYTU BioPharma worth $269 as of Q2 2026.
- Morgan Stanley left its AYTU BioPharma share count unchanged in Q2 2026.
- AYTU BioPharma made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #7801 holding.
- Morgan Stanley first reported a position in AYTU BioPharma in Q4 2019 and has held it in 27 quarters since.
- Morgan Stanley's AYTU BioPharma position peaked at $1.09M in Q3 2021.
- 38 funds tracked by Wall St. Rank held AYTU BioPharma as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.